Biotech Values

[DewDiligence]

AGN acknowledges VRX’s sweetened offer of $58.30 in cash plus 0.83 shares of VRX (an additional $10 in cash relative to the original offer):

http://finance.yahoo.com/news/allergan-confirms-receipt-revised-unsolicited-125200707.html

That roughly 2/3 of the new offer’s value consists of VRX stock is going to be a problem, IMO, because AGN doesn’t think much of VRX’s roll-up business model (and neither do I).